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1. Introduction 
Breast cancer is the most commonly diagnosed cancer in women. Resistance to therapy is 
the major reason for failure of cancer treatment (Mesner et al., 1997). There is a critical need 
to identify new chemotherapeutic agents that can increase susceptibility to anti-breast 
cancer drugs or overcome resistance mechanisms, which would improve patient outcomes, 
prevent relapse, and prolong patient survival. Kefir is an acidic and mildly alcoholic 
fermented milk that originated in the Caucasian mountains of former Soviet Union, and 
enjoys a rich tradition of health benefits. Consumption of fermented dairy foods has been 
associated with lower incidence of breast cancer (Ronco et al., 2002). Research on the 
putative health benefits of fermented milks suggested that by-products of bacterial 
fermentation of proteins, lipids and carbohydrates present in fermented milks exert health 
benefits beyond basic nutrition including anti-tumor action, immune system enhancement 
and antioxidant effects (Parvez et al., 2006). Conjugated linoleic acid (Schonberg et al., 1995), 
sphingolipids (Dillehay et al., 1994), polysaccharides (Shiomi et al., 1982), organic acids 
(Garrote et al., 2000) and some proteins and peptides (Svensson et al., 1999) have been shown 
to have antimutagenic and antitumor effects. Promising results regarding anti-tumor 
activity of yogurt extracts in cell culture (Biffi et al., 1997) and kefir extracts in animal 
feeding studies (Cervikbas et al., 1994; Furukawa et al., 2000; Shiomi et al., 1982) have been 
reported. However, the bioactive components in kefir and the mechanisms involved in the 
various biofunctional effects of kefir are still not well characterized, particularly in terms of 
anti-cancer activities. In our recent studies, kefir extracts exerted potent anti-proliferative 
effects on cultured human mammary tumor cells as compared to extracts of yogurt or milk 
(Chen et al., 2007). The aim of the present study was to fractionate and characterize bioactive 
components in kefir mother culture that exert antiproliferative effects in MCF-7 cells. 
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2. Materials and methods 
Kefir samples were provided by Liberte Inc. (Brossard, Canada). The large-scale production 
of kefir involves a two-step fermentation process. The first fermentation is achieved by 
directly adding kefir grains (2-10%) to milk that has been pasteurized and cooled to 20-25oC. 
After a period of fermentation lasting around 24 h, the grains are removed by filtration. The 
filtrate (kefir mother culture) is added to milk (1-3%), which is further fermented for 24 h 
and packaged for the consumer market (final kefir commercial product). Samples from three 
different batches were used. Upon receipt of the samples, they were immediately well 
stirred, and centrifuged at 4°C, 32,000 x g, for 60 min (Sorvall RC 5C Centrifuge, rotor ss-34, 
Sorvall Instruments, Wilmington, USA). The supernatant was filtered with a 0.45 µm 
membrane filter followed by a 0.2 µm filter. The filtrates were stored at −80°C for future use.  
2.1 Macronutrients and minerals 
A Flexi-Dry MP lyophilizer (FTS Systems Inc., Stone Ridge, USA) was used for triplicate 
determination of moisture. Ten grams of homogenized sample was transferred into pre-
weighed aluminium weigh boat, frozen at -80oC for approximately 1 h and then freeze dried 
for 48 h. The boat was weighed again and the moisture was calculated. A LECO FP-428 
Nitrogen Determination System (LECO Corporation, St. Joseph, USA) was used to 
determine nitrogen content in triplicate for freeze-dried samples. Crude protein content was 
calculated using a conversion factor of 6.25. Protein in solution was determined by using 
Bio-Rad protein assay kit according to the instruction with the kit (Bio-Rad Laboratories, 
Hercules, USA). Peptide concentrations were analyzed by the method of Church et al. (1983) 
(opthialdehyde; OPA). Crude fat was analyzed in triplicate with an automatic Soxtec 
extraction system (Soxtec HT6 Tecator AB, Hoganas, Sweden).  Three grams of freeze-dried, 
well-mixed sample was loaded and analyzed. Proper amount of freeze-dried samples were 
digested in 70% (w/v) nitric acid (Fisher Scientific, trace metal grade) and minerals (i.e., Ca, 
Mg, Zn, Fe, Na and K) were determined by using Hitachi Z-8200 Zeeman polarized atomic 
absorption spectrophotometer (Nissei Sango Ltd., Mississauga, ON, Canada). 
2.2 Organic acids 
Lactic acid content was analyzed using a Sigma lactate kit assay (Sigma Diagnostics, Cat. 
No. 735-10, St. Louis, USA). Organic acids were determined by HPLC according to the 
method of Guzel-Seydim et al. (2000). Five mL of each sample was diluted with 25 mL 0.01 
M H2SO4, vortexed for 1 min followed by centrifugation at 2000 x g for 10 min. Supernatants 
were collected and filtered through 0.2 µm filter. Volumes of 20 µl of samples and standards 
were injected into a Beckman Gold HPLC system (Beckman Coulter, Fullerton, USA) 
equipped with an Aminex HPX-87H (300 mm x 7.8 mm) organic acid column (Bio-Rad 
Laboratories, Hercules, USA). Degassed 8 mM sulfuric acid (H2SO4) was used as the mobile 
phase. The organic acids oxalate, citrate, malate, succinate, formate and acetate were 
detected at 215 nm. Organic acids were quantified using external standards (organic acid 
analysis standard, Bio-Rad Laboratories, Hercules, USA). 
2.3 Molecular weight cut-off fractionation (MWCO) 
Centriplus centrifugal filter devices were used to get MWCO fractions at 3000 Da (Millipore, 
Bedford, USA). Ten milliliters whole extract were loaded to the sample reservoir and the 
www.intechopen.com
Fractionation and Characterization of Bioactive Components  
in Kefir Mother Culture that Inhibit Proliferation of Cultured MCF-7 Human Breast-Cancer Cells 151 
assembled device was centrifuged at 4°C, 3000 x g for 290 min. The filtrates were collected 
for further analysis. 
2.4 Size exclusion HPLC (SEC) separation 
One hundred microliters of kefir mother culture extract was injected into a TSK G2000SWXL 
column (78 mm x 30 mm, SUPELCO, Bellefonte, USA) and separated with a Shimadzu LC-
6AD Liquid Chromatograph system (Shimadzu Scientific Instruments, Inc. Columbia, USA) 
with UV detection at 210 nm. The separation buffer used was a mixture of 45% acetonitrile 
in 0.1% trifluoroacetic acid (TFA) with a flow rate of 0.4 ml/min for 40 min. Nine fractions 
were collected for each HPLC run, and fractions from five to ten runs were pooled. The 
above nine fractions were evaporated with N2 and then freeze dried, stored at −80°C for cell 
culture incubations and for further analytical analyses. 
2.5 Reverse phase HPLC (RP-HPLC) fractionation 
The fraction(s) collected with SEC HPLC that showed antiproliferative effects on MCF-7 
cells were further analyzed with a Prosphere 300 C4 column (5µm, 250 mm x 4.6 mm) 
(Alltech Associate, Inc. Deerfield, USA) using a Beckman Gold HPLC System (Beckman 
Coulter, Fullerton, USA). After the column was equilibrated with buffer A (0.1% TFA in 
water) at a flow rate of 1 ml per min, the fractions were eluted with a linear gradient of 
buffer A (0.1% TFA in water) and buffer B (60% of acetonitrile in 0.1% TFA: 40% of 0.1% 
TFA in water) as follows: 0 to 60 min, 0 to 90% B; and 61 to 65 min, 90 to 0% B. Dual channel 
absorbance was monitored at 210 nm (channel A) and 280 nm (channel B). 
2.6 Preparative HPLC fractionation 
Three batches of extracts of kefir mother culture were pooled and fractionated using the 
Centriplus centrifugal filter devices to obtain fractions of compounds with molecular 
weights less than 3000 Da. The fractions of MWCO less than 3000 Da were freeze-dried 
using a FLEXI-DRY MP Freeze Dryer (FTS Systems, Inc. Stone Ridge, U SA). Five g of the 
lyophilized MWCO fractions were dissolved in 20 ml of water. Ten milliliters of 
reconstituted solution were loaded on a C4 preparative column (300 Å, 5 µm, 300 mm x 50 
mm) (Vydac Company, Herperia, CA) and separated with a Water Delta Prep 4000 HPLC 
system (Waters Corporation, Milford, USA). After the column was equilibrated with buffer 
A (0.6% acetic acid in water) at a flow rate of 13 ml and the fractions were eluted with a 
linear gradient of buffer A and buffer B (0.6% acetic acid in acetonitrile) as follows: 0 to 70 
min, 0 to 60% B; 70 to 80 min, 60 to 70% B; 80 to 100 min, 70 to 80% B; 100 to 105 min, 80 to 
0% B. A total of 100 fractions were collected between 0 and 100 min, with samples taken at 
1-min intervals. The fractions were then lyophilized and kept at −80°C for further cell 
culture and analysis. The fractions were reconstituted by adding water and peptide and 
protein concentrations were determined before cell culture assays. 
2.7 Capillary electrophoresis 
Capillary zone electrophoresis (CE) was performed using a P/ACE TM 2200 HPAC 
instrument controlled by System Gold software (Beckman, Fullerton, CA, USA) coupled to 
an IBM PC 486 computer (IBM Corp., Portmouth, England) for data acquisition and 
analysis. A neutral uncoated fused silica capillary column (57 cm × 50 µm, the length from 
intake to detector was 50 cm) was assembled in the P/ACE cartridge (Polymicro  
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Technologies, Phoenix, Arizona USA) for capillary separations. Injection volume, buffer 
concentration and running voltage were optimized to achieve the best resolution with the 
shortest running time. The capillary was flushed with 1 M sodium hydroxide, followed by 
nanopure water, 0.1 M sodium hydroxide, nanopure water, 1 M hydrochloric acid, and 
again water, each for 5 min at a pressure of 40 psi. A solution of 5% polybrene and 2% 
ethylene glycol was then passed for 10 min at 40 psi. Excessive coating was then removed 
by flushing with water for 2 min. Further capillary flushing was then performed for 
additional 10 min using 200 mM formic acid buffer. Before each sample application, the 
capillary was rinsed with 1 min water, 1 min 0.1 M sodium hydroxide, 1 min water and 3 
min separation buffer (200 mM formic acid in water, pH 2.0). After the completion of each 
run, the capillary was rinsed with nanopure water for 1 min, 0.1 M sodium hydroxide for 
1 min and nanopure water for 1 min. Peptide standard and sample injections were carried 
out at the anode end of the capillary using N2 pressure (0.5 psi) for 5 sec and was 
separated at a constant temperature of 20°C with a 200 mM formic acid (pH 2.0) as 
separation buffer. On-line detection was performed using an UV detector at 200 nm. 
Twenty kilovolts was applied across the run buffers for best separation. The capillary was 
re-coated after every 5 runs. 
2.8 MALDI-TOF for estimation of molecular weight 
Reconstituted SEC-HPLC and RP-HPLC fractions were analyzed using a MALDI-TOF mass 
spectrometer (Voyager DE-STR; Applied Biosystems, Palo-Alto, CA, USA) with a laser at 
337 nm and an acceleration voltage of 20.000 V. 
2.9 Mass spectrometry 
Mass spectrometric analysis in the positive ion mode was performed on a triple quadupole 
mass spectrometer (SCIEX API III Biomolecular mass analyzer, Thornhill, Ontario, Canada). 
Lyophilized reversed phase HPLC fractions having antiproliferative effect on MCF-7 cells 
were reconstituted in 0.5 mM ammonium acetate in methanol or in 10% acetic acid in 20% 
aqueous methanol. The resulting solution was then infused into the electrospray ion-source 
by a syringe pump (Harvard Apparatus Model 22, South Natick, MA) at a flow rate of 1.5 
ml/min. The ion-spray voltage was set at 5.5 kV and the orifice potential was set at 50 V. 
Argon was used as the collision gas at a collision gas thickness (CGT) of 1.5 x 1014 for 
collision-induced fragmentation MS-MS analysis.  
2.10 Cell Culture screening for antiproliferative effects 
MCF-7 cells were purchased from ATCC (ATCC, Manassas, USA). Cells were routinely 
propagated as a monolayer culture in Dulbcco’s Modified Eagle Medium (DMEM) (Gibco, 
Grand Island, NY, USA) supplemented with 10% heat-inactivated fetal bovine serum (FBS) 
(Gibco, Grand Island, NY, USA), in a 75-cm2 plastic dish at 37°C in a humidified atmosphere 
with 5% CO2, and passaged every 3-4 days. Normal human mammary epithelial cell lines 
(HMEC) were graciously provided by Dr. M.R. Stampfer (Lawrence Berkeley National 
Laboratory, Berkeley, USA). Cells were routinely propagated as a monolayer culture in 
Mammary Epithelial Growth Media (MEGM, Clonetics, San Diego, USA) supplemented 
with 10% heat-inactivated fetal bovine serum (FBS) in 75-cm2 plastic dish at 37°C in a 
humidified atmosphere with 5% CO2, and passaged every week. For the experiments, both 
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MCF-7 and HMEC cells were harvest from the dish using 0.25% trypsin-EDTA solution 
(Sigma, St Louis, MO, USA). 
2.11 Cell proliferation experiments in 24-well plates 
Cells previously harvested were seeded in 24-well plates, i.e., 10,000 cells for MCF-7 per well 
in DMEM supplemented with 10% FBS and 5,000 cells for HMEC per well in MEGM 
supplemented with 10% FBS. The cells were allowed to attach for 24 h. After that period, old 
media were removed and fresh media and extracts were added to each well. To study the 
dose response, a serial dilution of each the extract using the culture media was made to 
achieve final concentrations of extracts at 5%, 2.5%, 1.3%, 0.6%, and 0.3% (vol./vol.), 
respectively. Because the kefir extracts were acidic (approximately pH 4.5), Dulbecco’s 
Phosphate Buffered Saline (PBS) buffer (Gibco BRL, Grand Island, NY) was added to the 
culture media to adjust the pH between 7.0 and 7.4. Cells were incubated at 37°C in a 
humidified atmosphere with 5% CO2 for 6 d. Cell nuclei were counted in order to eliminate 
the difficulty in counting whole cells due to clumping. Furthermore, a more uniform 
distribution of nuclei over the grids of a hemacytometer was seen compared with whole 
cells. Media was aspirated from wells and cells were rinsed with 500 µl of PBS. 250 µl of 
hypotonic buffer (0.01 M HEPES, 1.5 M MgCl2, pH 7.5) was added to each well. After 2 min, 
250 µl of cell lysing solution (10% ethyl hexadecyl dimethyl ammonium bromide, 3% glacial 
acetic acid, in water) was added. The plate was shaken lightly every minute for 5 min. Cell 
lysis was confirmed microscopically as indicated by a suspension of clean nuclei. The 
suspension was mixed and the nuclei were counted using a Coulter Counter (Coulter 
Counter Corporation, Fullerton USA). Each sample was run in quadruplicate. Control cells 
were incubated with the culture medium with the dosing vehicle (PBS). To standardize 
results, each plate had its own control wells with cells treated with PBS and cell proliferation 
of different treatment was expressed as a percent of control. 
2.12 Cell proliferation experiments in 96-well plates 
Cells previously harvested were seeded in 96-well plates at 1,000 cells per well for MCF-7 in 
DMEM supplemented with 10% FBS and for HMEC in MEGM supplemented with 10% FBS. 
The cells were allowed to attach for 24 h. After that period, old media were removed and fresh 
media and extracts were added to each well. A serial dilution of each test fraction was made to 
study the dose-response. PBS buffer was added to the culture media to keep the final pH 
between 7.0 and 7.4. Cells were incubated at 37°C in a humidified atmosphere with 5% CO2 for 
6 d and the cell numbers in each well were determined by using a CellTiter 96® Aqueous One 
Solution Cell Proliferation Assay kit (Promega, Madison, USA). Each sample was run in 
quadruplicate. Control cells were incubated with the culture medium with the dosing vehicle 
(PBS). To standardize results, each plate had its own control wells with cells treated with PBS 
and cell proliferation of different treatments was expressed as a percent of control. 
2.13 Statistics 
All statistics test were performed using SAS 8.2 for PC (SAS, Cary, NC USA). Means were 
compared with Student’s t test. Two-way ANOVA was used to analyze the effects of 
treatments and doses for the cell culture experiments. The differences among doses and 
treatments were determined by the Student-Newman-Keuls (SNK) multiple comparison 
test. Statistical significance was considered at   P< 0.05.  
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3. Results  
Moisture, macronutrients and some minerals in kefir mother culture and final kefir 
described in Table 1.  
 
Component 
Batch 1 Batch 2 Batch 3 
Mother 
culture Kefir 
Mother 
culture Kefir 
Mother 
culture Kefir 
Moisture (g) 189.78±0.09 90.40±0.06 91.22±0.19 90.03±0.02 89.56±0.07 90.17±0.08 
Ash (g) 0.68±0.005  0.67±0.004 0.66±0.006  0.70±0.003 0.68±0.002  0.67±0.003 
Protein (g) 3.05±0.16  2.81±0.03 2.78±0.03  3.14±0.04 3.28±0.01  2.77±0.02 
Fat (g) 2.32±0.06  1.77±0.04 2.46±0.06  1.46±0.02 2.36±0.04  1.48±0.01 
Calcium (mg) 78.20±0.66 77.70±0.71 78.93±0.58 77.40±0.64 81.53±0.73 80.40±0.56 
Iron (mg) 0.02±0.001 0.02±0.001 0.02±0.001 0.02±0.001 0.02±0.001 0.02±0.001 
Zinc (mg) 0.28±0.02 0.29±0.02 0.28±0.02 0.30±0.02 0.31±0.03 0.29±0.03 
Magnesium (mg) 8.42±0.55 8.65±0.35 8.88±0.56 8.40±0.71 8.97±0.48 8.70±0.42 
Sodium (mg) 28.51±1.86 29.0±0.71 28.60±2.03 30.05±2.05 30.99±1.08 31.05±0.72 
Potassium (mg) 60.28±0.89 60.60±0.42 59.36±1.16 61.30±1.34 60.40±1.08 60.95±0.78 
Table 1. Nutrient composition from three different batches of kefir mother culture and final 
commercial kefir product  (per 100 g wet weight) (1Mean±SD, n=3).  
No significant differences among nutrients and organic acids were found, except that lactic 
acid in the kefir commercial product was higher than that of kefir mother culture (Table 2). 
 
Component Mother culture Kefir 
Lactic acid1 377.86±8.94 106.87±9.36* 
Uric acid 2 0.014±0.003 0.012±0.002 
Pyruvic acid2 0.54±0.15 0.52±0.10 
Oxalic acid2 4ND ND 
Citric acid2 3.27±0.17 3.22±0.28 
Malic acid2 54.79±9.25 57.62±11.01 
Succinic acid 2 1.61±0.24 1.71±0.08 
Formic acid2 Not detectable Not detectable 
Acetic acid2 3.81±0.74 3.46±0.47 
Table 2. Organic acid concentrations (mmol/l) in mother culture and final kefir commercial 
product (1Determined by lactic acid kit assay method; 2Determined by HPLC method of 
Guzel-Seydim et al. (2000); 3Mean±SD, n=3; 4ND = Not detectable; *P < 0.05). 
Capillary electrophoresis analyses showed that the profiles of extracts of mother culture and 
kefir were similar (data not shown). In our earlier study, the extract of kefir mother culture 
showed a tendency of having stronger antiproliferative effect on MCF-7 cells than other 
extracts (Chen et al., 2007). Hence, mother culture was chosen for further fractionation and cell 
culture tests to identify the bioactive component(s). Extracts of kefir mother culture that were 
fractionated via the 3000 Da MWCO were analyzed for protein and peptide content (Table 3).  
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Samples Moisture (g/100g) 
Crude protein1 
(g/100g) Protein
2 (µg/ml) Peptides
3  
(mmol/l) 
Whole extract 496.39±0.24 0.27±0.03 152.91±11.53 5.53±0.26 
MWCO<3000 5ND ND 5.10±0.07* 4.21±0.32* 
MWCO>3000 ND ND 195.94±4.11* 7.16±0.36* 
Table 3. Protein and peptide concentrations in different MWCO fractions of extracts of kefir 
mother culture (1Determined by using Nitrogen Determinator; 2Determined by Bradford 
method (1976); 3Determined by OPA method of Church et al. (1983); 4Mean±SD, n=3; 5ND: 
No data is available; *Significant different at P < 0.05 when compared to protein or peptide 
concentration in whole extract). 
Both protein and peptide concentrations were significantly lower in the fraction of MWCO 
less than 3000 Da (P < 0.05) relative to the whole kefir mother culture extract. Both the whole 
extract and the fraction with the MWCO less than 3000 Da were screened by MCF-7 cell 
culture using 24-well plates. As shown in Figure 1, the filtrate of MWCO less than 3000 Da 
had a dose dependent antiproliferative effect on MCF-7 cells comparable to that of the 
whole mother culture extract. 
 
 
Fig. 1. Antiproliferative effects on MCF-7 cells induced by extracts of: (A) whole kefir 
mother culture; and (B) fraction of kefir mother culture obtained with MWCO less than 3000 
Da. Cell proliferation was analyzed in 24-well plate. Values were graphed as Mean±SD, n=4. 
The kefir mother culture filtrate that contained the MWCO less than 3000 Da was further 
separated with SEC-HPLC. Nine fractions were collected with each run with retention times 
of 14.6 to 17.0, 17.1 to 19.0, 19.1 to 21.0, 21.1 to 23.7, 23.8 to 25.6, 25.7 to 27.3, 27.4 to 29.1, 29.2 
to 31.6, 31.7 to 33.7 min, respectively. Ten runs of SEC-HPLC fractions were pooled, freeze-
dried and reconstituted in 2 ml water. The estimated molecular weight, protein and peptide 
concentrations are shown in Table 4. All the nine fractions were tested with MCF-7 cells in 
96-well plates for their antiproliferative effects.  
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Fraction Retention time 
(min) 
Molecular Weight 
(Dalton) 
Protein 
(µg/ml) 
Peptides 
(µM/l) 
1 14.4-17.0 13116-29507 145.7±5.12 274.53±2.19 
2 17.1-19 7618-12745 118.56±4.89 284.70±5.31 
3 19.1-21 4672-7425 43.62±2.84 208.33±2.26 
4 21.1-23.7 2588-4565 16.80±1.56 491.14±6.67 
5 23.8-25.6 1776-2535 3.23±0.26 422.01±5.17 
6 25.7-27.3 1297-1742 2.92±0.2 655.11±4.58 
7 27.4-29.1 949-1274 1.38±0.12 1168.33±8.22 
8 29.2-31.6 635-934 4.77±0.16 1053.71±5.17 
9 31.7-33.7 470-625 3.84±0.22 224.59±1.93 
Table 4. Estimated molecular weight, protein and peptide concentration of the nine 
SEC HPLC fractions, Mean±SD, n=3. 
Fractions 7 and 8 were the only fractions to demonstrate a dose-dependent antiproliferative 
effects on MCF-7 cells with the most potent effect exhibited with fraction 7 (Figure 2).  
 
 
Fig. 2. Antiproliferative effects of 9 SEC-HPLC fractions on MCF-7 cells. Cell proliferation 
was analyzed in 96-well plate using a CellTiter 96® Aqueous One Solution Cell Proliferation 
Assay kit. Values were graphed as Mean±SD, n=4. 
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Fraction 7 was also tested with HMEC cells, and no antiproliferative effects were observed 
(Figure 3). Fraction 7 was further analyzed with RP-HPLC, which showed the presence of 
about 11 peaks in Fraction 7 (Figure 4). SEC-HPLC Fraction 7 was also analyzed via MALDI-
TOF, which indicated that the peak masses ranged from 659 to 2074 Da. (Figure 5). 
 
 
Fig. 3. Antiproliferative effects of SEC-HPLC Fraction 7 on MCF-7 and HMEC cells. Cell 
proliferation was analyzed in 96-well plate using a CellTiter 96® Aqueous One Solution Cell 
Proliferation Assay kit. Values were graphed as Mean+SD, n=4. 
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Fig. 4. Elution profile of SEC-HPLC Fraction 7 of kefir mother culture using RP-HPLC. A 
Prosphere 300 C4, 5 µm, 250 mm x 4.6 mm column was used. After the column was 
equilibrated with buffer A (0.1% TFA in water) at a flow rate of 1 ml per min, the fractions 
were eluted with a linear gradient of Buffer A (0.1% TFA in water) and Buffer B (60% of 
acetonitrile in 0.1% TFA: 40% of 0.1% TFA in water) as follows: 0 to 60 min, 0 to 90% B; and 
61 to 65 min, 90 to 0% B. Absorbance was monitored at channel A 210 nm and channel B 280 
nm. The retention times of the peaks 1 to 11 are 15.4, 18.6, 21.1, 23.3, 26.1, 39.1, 43.7, 44.5, 
45.2, 46.3, and 50.1 min, respectively. 
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Fig. 5. Mass spectrogram of SEC-HPLC Fraction 7 of kefir mother culture analyzed by a 
MALDI-TOF mass spectrometer with a laser at 337 nm and an acceleration voltage of  
20.000 V. 
A preparative C4 column was utilized to obtain sufficient amounts of mother culture kefir 
fractions of MWCO less than 3000 Da for more extensive structure analysis and cell culture 
studies. The average nitrogen content of the lyophilized filtrate of MWCO less than 3000 Da 
was 0.58%. Five g of the lyophilized MWCO less than 3000 Da fractions was dissolved in 20 
ml of water. Ten milliliters of reconstituted solution were loaded on the column, and 100 
fractions were collected in 1 min intervals (Figure 6).  
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Fig. 6. Elution profile of MWCO less than 3000 Da fraction of kefir mother culture extract 
analyzed by preparative RP-HPLC. Appropriate amount of samples were loaded on a C4 
preparative column (300 Å, 5 µm, 300 mm x 50 mm) (Vydac Company, Herperia, CA) and 
separated with Waters Delta Prep 4000 HPLC system. After the column was equilibrated 
with buffer A at a flow rate of 13 ml, the fractions were eluted with a linear gradient of 
Buffer A (0.6% acetic acid in water) and Buffer B (0.6% acetic acid in acetonitrile) as follows: 
0 to 70 min, 0 to 60% B; 70 to 80 min, 60 to 70% B; 80 to 100 min, 70 to 80% B; 100 to 105 min, 
80 to 0% B. The absorbance was measured at 210 nm. A total of 100 fractions were collected 
between 0 and 100 min, with samples taken at 1-min intervals.  
The peptide concentration of each preparative HPLC fraction is shown in Figure 7, Fractions 
28 to 58, 62 to 64, and 72 to 74 were screened for antiproliferative effects on MCF-7 cells with 
three concentrations of 0.4%, 2% and 10% (Figure 8).  
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Fig. 7. Peptide concentrations in preparative RP-HPLC fractions. One hundred fractions 
obtained from preparative RP-HPLC were freeze-dried and then reconstituted with 
nanopure water to certain concentration. Peptide concentrations were determined in 
triplicates by OPA method. Mean values were plotted. 
 
 
Fig. 8. Antiproliferative effects of fractions of preparative RP-HPLC on MCF-7 cells. Cell 
proliferation was analyzed in 96-well plate using a CellTiter 96® Aqueous One Solution Cell 
Proliferation Assay kit. Each fraction was diluted at three concentrations and was run in 
quadruplicate. Mean values were plotted. 
0
2
4
6
8
10
12
14
16
1 6
1
1
1
6
2
1
2
6
3
1
3
6
4
1
4
6
5
1
5
6
6
1
6
6
7
1
7
6
8
1
8
6
Fractions
P
e
p
ti
d
e
s
 c
o
n
te
n
t 
(m
m
o
l/
L
)
0
20
40
60
80
100
120
140
28 30 32 34 36 38 40 42 44 46 48 50 52 54 56 58 62 64 72 74
Fractions
%
 o
f 
c
o
n
tr
o
l
10%
2%
0.4%
www.intechopen.com
 
Breast Cancer – Current and Alternative Therapeutic Modalities 162 
Fractions 29 to 41, 62 were found to have antiproliferative effects on MCF-7 cells. These 
fractions were further screened for antiproliferative effects with serial dilution. A dose 
dependent antiproliferative effect was observed when MCF-7 cells were treated with 
fractions 29, 30, 34, and 37, while not on HMEC cells (Figure 9). 
 
  
                                   A                                                                       B  
 
  
                                   C                                                                       D 
 
Fig. 9. Dose effect of preparative RP-HPLC Fraction 29 (A), 30 (B), 34 (C), and 37 (D) on 
MCF-7 and HMEC cells. Cell proliferation was analyzed in 96-well plate using a CellTiter 
96® Aqueous One Solution Cell Proliferation Assay kit. Values were graphed as Mean±SD, 
n=4. 
Tamoxifen is a commonly used medication for breast cancer patients. In this study, only the 
dosage above 0.2 µM/l showed antiproliferative effects on MCF-7 cells. The effective dose 
reported here was higher than the value reported by Doisneau-Sixou et al. (2003). RP-HPLC 
Fraction 30 of kefir mother culture extract significantly increased MCF-7 cell susceptibility to 
tamoxifen (Figure 10). A dose dependent antiproliferative effect was also observed.  
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Fig. 10. Antiproliferative effect of RP-HPLC Fraction 30 of kefir alone or in combination with 
tamoxifen on MCF-7 cells. Means±SD (n=4) with the same letter are not significantly 
different at P < 0.05 for comparison among treatments at the same dose level. 
Electrospray mass spectrometry was used to determine the molecular weight profile of the 
active Fractions 29, 30, 34, and 37. Figure 11 is the ESI-mass spectrum of HPLC fraction 30. 
The spectrum represents a typical molecular ion profile of the active HPLC fractions (29, 30, 
34 and 37). The similarity in the molecular ion profile of the active fractions indicated that 
the active component(s) is spread over HPLC Fractions 30 to 37. The spectrum showed 
mainly singly charged molecular ions with m/z ratios ranging from 300 to 900. The peaks 
appearing below m/z 300 were found to be fragments of the peaks with m/z ranging from 
300 to 900. 
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Fig. 11. Mass spectrum of HPLC Fraction 30 done by electrospray mass spectrometry. The 
mainly singly charged molecular ions with m/z ratios range from 300 to 900. The peaks 
appearing below m/z 300 were found to be fragments of the peaks with m/z ranging from 
300 to 900. 
To characterize the composition and chemical structure of the active components in the 
HPLC fractions, molecular ions ranging from m/z 300 to 900 were subjected to collision ion 
dissociation (CID) tandem mass spectrometry. Figure 12A, showed the CID spectrum of the 
molecular ion at m/z 821. Fragmentation of the molecular ion at m/z 821 produced a 
neutral loss of 342 mass units, which corresponds to the loss of a lactose moiety. It also 
produced a series of neutral loses of 60 mass units, which correspond to the loss of acetic 
acid moieties.  The neutral loss of 60 atomic mass units may also be derived from sugar 
cleavage products (Figure 13). The CID spectrum of the molecular ion at m/z 813 (Figure 
12B) also produced a neutral loss of 342 (lactose) and neutral losses of 120 atomic mass units, 
which may be derived from fragmentation of lactose (Figure 13). A neutral loss of 162, 
which corresponds to the loss of a hexose moiety (glucose or galactose), is also observed. 
This was also observed at m/z 759. The fragmentation patterns of the molecular ions at m/z 
821 and 813 indicate that they have similar structural features. The molecular ions with m/z 
707 (Figure 12E) and 723 (Figure 12D) represent sodium and potassium ion dimmers of 
lactose, respectively. The peaks at m/z at 365 and 381 represent the sodium and potassium 
ions of lactose respectively (Figure 14). 
Another interesting feature about the fragmentation pattern of with m/z ranging from 707 
to 823 is that they fragmented into common fragment ions at m/z 261 and 98. Further 
isolation and fragmentation (MS-MS) of the ion at m/z 261 showed that its major product 
ion is the ion at m/z 98. Further isolation and fragmentation of the ion at m/z 98 produced 
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two ions at m/z 54 and 39. The tandem mass spectrometric analysis of the molecular ion of 
the active HPLC fraction show that most of the peaks produced a stable product ion at m/z 
98, but the ion at 98 could not be ascribed to known structure peptide. Analysis of the 
fragmentation pattern of the molecular ion at m/z 759 (Figure 12C), however, revealed that 
the molecular ion could be derived from the interaction between serine and lactose.  
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Fig. 12. Spectrum of molecular ion at m/z = 821 (A), m/z=813 (B), m/z= 759 (C), m/z=723 
(D), and m/z=707 (E) done by collision ion dissociation (CID) tandem mass spectrometry. 
As indicated in Figure A, fragmentation of the molecular ion at m/z 821 produced a neutral 
loss of 342 and 60 mass units, which corresponds to the loss of a lactose moiety and acetic 
acid moiety respectively. There is also a neutral loss of 98, which could not be ascribed to a 
known structure. Ion at m/z =261 was also observed. Fragmentation of the molecular ion at 
m/z 813 produced a neutral loss of 342 and 120 mass units, which might be derived from 
lactose and hexose moieties (glucose or galactose) respectively. Fragmentation of the 
molecular ion at m/z 759 produced a neutral loss of 342 and serial loss of 60 mass units. 
Fragmentation of the molecular ion at m/z=723 produced neutral losses of 342 and 120 
atomic mass unit. The main fragment is the ion at m/z 365 with the neutral loss of 342 
(lactose) from m/z 707. 
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Fig. 13. Scheme 1: Generation of neutral loss of 60 and 120 atomic mass unit from 
fragmentation of lactose. Fragmentation at “a” and “b” will generate a neutral loss of 60 and 
fragmentation at “a” and “c” will generate a neutral loss of 120 atomic mass unit. They can 
be derived from fragmentation of acetic acid and lactose. 
 
 
Fig. 14. Spectrum of molecular ion at m/z 365 and 381 done by collision ion dissociation 
(CID) tandem mass spectrometry. The peaks at m/z at 365 and 381 represent the sodium 
and potassium ions of lactose respectively. 
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A possible scheme for the generation of the ion at m/z 759 is presented in Scheme 2 (Figure 
15). The proposed structure agrees with the fragmentation pattern. This interaction may be 
due to chemical reactions. The interaction between the amino group of serine and the 
reducing end of lactose is likely a chemical reaction similar to the Maillard reaction, and the 
interaction between the hydroxyl groups of lactose and the carboxyl group of serine is a 
simple esterification reaction. The reactions, particularly the esterification reaction may also 
be driven biochemically by esterases. The active fraction likely still contains a mixture of 
chemicals as suggested by the results of RP-HPLC (Figure 16). The exact molecular structure 
of these compounds is not known. However, results of the extensive MS analysis suggested 
that the compounds are possibly complex polymers that have lactose as the backbone 
structure. The proposed structure shown in Scheme 2 is a product with two lactose units 
linked by a serine. A more complex molecule with linkage with acetic acid is also possible.  
 
 
Fig. 15. Scheme 2: A possible interaction for the generation of the ion at m/z 759. As shown 
in the scheme, the interaction between the amino group of serine and the reducing end of 
lactose is likely a chemical reaction similar to the Maillard reaction, and the interaction 
between the hydroxyl groups of lactose and the carboxyl group of serine is a simple 
esterification reaction. The reactions, particularly the esterification reaction may also be 
driven biochemically by esterases. 
The isolated bioactive fraction showed antiproliferative effects on cancer cells while not on 
normal cells. As indicated in the RP-HPLC chromatograph, the isolated fractions such as 
Fraction 30 are likely composed of multiple components that may be acting either singly or 
synergistically to exert the antiproliferative effects. Although the presence of peptides was 
suggested in the fractions as determined by the OPA methodology, the MS data did not 
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support the presence of known peptide structures. The failure to identify any known 
peptides is likely due to the limitation of the OPA method, which can only detect the 
presence of primary amines and thus the primary amines in peptides cannot be 
differentiated from other amine containing compounds.  
 
 
Fig. 16. Chromatograph of preparative HPLC Fraction 30 done by RP-HPLC. 50 µl of 
reconstituted preparative HPLC Fraction 30 which showed antiproliferative effect on MCF-7 
cells was injected into a Prosphere 300 C4 column (5 µm, 250 mm x 4.6 mm) (Alltech 
Associate, Inc. Deerfield, IL 60015, USA) on Beckman HPLC System and eluted with a linear 
gradient of Buffer A (0.1% TFA in water) and Buffer B (60% of acetonitrile in 0.1% TFA: 40% 
of 0.1% TFA in water) as follows: 0 to 60 min, 0 to 90% B; and 61 to 65 min, 90 to 0% B. 
Absorbance was monitored at channel A 210 nm. 
4. Conclusion  
Due to the complex mixture of components in the specific fractions and the whole kefir 
extracts, the antiproliferative role of specific components such as proteins, peptides, organic 
acids and some small molecules, such as free amino acids, oligosaccharides and their 
interactions has been unclear. One of the main components of the bioactive antiproliferative 
kefir fractions is composed of lactose and acetic acid, possibly an end product of 
fermentation of the milk protein and sugar by the kefir bacteria and yeast. The lactose 
polymer suggests that the active component may be fragments of previously isolated 
polysaccharides termed as kefirans (Kooiman, 1968). Kefiran is a water-soluble 
polysaccharide consisted of approximately equal proportions of D-glucose and D-galactose 
(Kooiman, 1968; Micheli et al., 1999). Kefiran has been reported to have antitumor activity 
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(Shiomi et al., 1982; Murofushi et al., 1983). It was also shown to be one of the substances 
having few or no side effect(s) in functioning to retard tumor growth in vivo. 
It is noteworthy that one of the proposed novel bioactive structures contains serine and 
glucose or galactose; hence, it is conceivable that this molecule could be a sphingolipid 
compound. The ceramide component of sphingolipids is derived from serine and 
sphingolipids such as cerebrosides, which contain either a glucose or galactose. 
Sphingolipids such as gangliosides are sphingosine compounds that contain several glucose 
or galactose units. Also, lower molecular weight ceramide moieties have been detected in 
dairy gangliosides (Colarow et al., 2003) and cultured dairy products have been shown to be 
a rich source of gangliosides (Kathleen et al., 2000). Ceramide is derived from sphingomyelin 
(SpM) and can act as an intracellular second messenger for tumor necrosis factor-alpha, IL-
1beta, and other cytokines. Ceramide has also been implicated in the acquired drug 
resistance that often characterizes breast cancer cells (Liu et al., 1999). C2 and C6 ceramides 
are cell permeable ceramide analogs that have been shown to induce cell apoptosis (Fillet et 
al., 2003). Osada et al. (1993) demonstrated that kefir contains an active substance, which 
enhances IFN-beta secretion of a human osteosarcoma line MG-63 treated with a chemical 
inducer, poly I: poly C. The active substance in the fermented milk was identified to be SpM. 
SpM from fermented milk (F-SpM) was a mixture of four molecular species of SpMs having 
C21-, C22-, C23- and C24-fatty acids. F-SpM enhanced the IFN secretion 14 times; SpMs 
from other food sources also enhanced IFN secretion but more moderately (2-3 times). We 
have observed a synergistic effect when MCF-7 cells were treated with ceramide analogs in 
the presence of extract of mother culture (data not shown). The putative sphingolipid 
component(s) in kefir that we have detected may have acted synergistically with the 
ceramide analogs leading to apoptosis of MCF-7 cells. In support of this concept, SpM has 
been shown to enhance the ceramide formation and ceramide-induced apoptosis in concert 
with the chemotherapeutic agent, gemcitabine, in human pancreatic cancer cells (Modrak et 
al., 2004). Modification of ceramide metabolism also increases MCF-7 cells sensitivity to 
cytotoxics (Lucci et al., 1999).  
In summary, we have isolated the bioactive components from kefir mother culture that 
show antitumor cell proliferative effects. The MS data indicate that the isolated compounds 
are likely SpM complexes such as gangliosides that might have anti-tumor activities that are 
similar to that of ceramide. The biological functions of these ceramide-like compounds 
warrant further studies. The appearance of multiple components in the isolated bioactive 
antitumor fractions suggests the possibility that such components may be acting both 
independently and synergistically to exert the antiproliferative effects. Instead of searching 
for single compound in kefir, a mixture or a combination of components may be the best 
approach to have the highest potency for antitumor properties. The potential of using the 
kefir extract as co-drug for chemotherapy should be explored. In that regard, RP-HPLC 
Fraction 30 increased significantly the susceptibility of MCF-7 cells to tamoxifen, a 
commonly used anti-breast cancer drug. These results thus provide the rationale for future 
research to explore the potential of using kefir extracts as co-drugs for breast cancer 
chemotherapy and/or a functional food used for prevention of breast cancer. 
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